Business Context and Reporting Period
Company: Greatbatch, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-K Annual Report
Period Ended: December 30, 2005
Business Overview: Greatbatch is a leading developer and manufacturer of batteries, capacitors, feedthroughs, enclosures, and other components for implantable medical devices (IMDs) through its Implantable Medical Components (IMC) segment. It also produces high-performance batteries for commercial applications (oil and gas, aerospace, oceanographic) through its Electrochem Commercial Power (ECP) segment. In 2005, the company expanded into value-added assembly, opening a new facility in Tijuana, Mexico.
Key Financial Metrics
| Metric | 2005 | 2004 (Restated) |
|---|---|---|
| Total Sales | $241.1 million | $200.1 million |
| Net Income | $10.1 million | $14.2 million |
| Diluted EPS | $0.46 | $0.66 |
| Operating Cash Flow | $43.3 million | $43.5 million |
| Gross Margin | 35.6% | 38.3% |
| Operating Margin | 7.0% | 13.5% |
| Working Capital | $152.0 million | $132.4 million |
| Long-Term Debt | $170.0 million (Convertible Notes) | $170.0 million |
| Cash & Short-Term Investments | $112.1 million | $92.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Total sales increased 20% to $241.1 million, driven by a 20% increase in IMC sales (due to higher demand for ICD batteries and feedthroughs) and a 21% increase in ECP sales (driven by oil and gas market dynamics).
- Profitability Decline: Despite revenue growth, Net Income decreased 29% to $10.1 million. Operating income dropped 37% to $16.9 million.
- Cost Pressures: Gross margin contracted by 2.7 percentage points due to lower selling prices, excess capacity at new facilities (Tijuana and wet tantalum capacitor plant), and higher warranty costs.
- Restructuring Charges: "Other operating expense" surged 305% to $18.6 million, primarily due to $18.6 million in charges related to facility consolidations (Alden, Carson City, Columbia, Tijuana), severance, and asset write-downs.
- Restatement: 2004 financial statements were restated to correct an error in the provision for income taxes, reducing 2004 net income by $2.0 million.
Guidance, Outlook, and Risks
- 2006 Outlook: Management expects net sales to increase 2% to 10%. IMC sales are projected to grow 1% to 10%, while ECP sales are expected to grow 6% to 12%.
- Cost Outlook: Other operating expenses are expected to range from $10.0 million to $12.5 million in 2006, primarily for ongoing plant consolidations. SG&A is expected to increase by $3.7 to $4.3 million due to the adoption of SFAS No. 123(R) regarding stock-based compensation.
- Key Risks:
- Customer Concentration: Three customers (Guidant, St. Jude Medical, Medtronic) accounted for approximately 70% of total sales in 2005.
- Raw Materials: Reliance on limited suppliers for critical materials (lithium, tantalum, platinum) exposes the company to price volatility and supply interruptions.
- Intangible Assets: Intangible assets represent 42% of total assets ($215.2 million); impairment risks exist if future cash flows do not meet projections.
- Regulatory & Tax: An IRS audit is questioning the deductibility of interest expense on convertible notes, potentially creating an additional $3.5 million tax liability if fully disallowed.
Investor Verification Checklist
- Verify the impact of the 2004 financial restatement on year-over-year growth comparisons.
- Monitor the execution of facility consolidations (Tijuana, Alden, Columbia) to ensure projected cost savings are realized and excess capacity costs decline.
- Assess the stability of the top three customers (Guidant, St. Jude, Medtronic), which represent 70% of revenue.
- Review the status of the IRS audit regarding the convertible note interest deduction and potential tax liability.
- Track the adoption of SFAS No. 123(R) in 2006 and its impact on reported net income (estimated $5.0-$6.0 million pre-tax expense).